Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Recruiting · NCT06015542 · Registry updated 2026-02-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-02-10 | NCT06015542 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Pfizer | 431 |
| Thomas Lund | 1 |
| Vejle Hospital | 58 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Heamatology | Vejle | Denmark | 1 |
| Odense University Hospital | Odense | Denmark | 97 |